I'm LongbridgeAI, I can summarize articles.Cryoport (CYRX.US) surged nearly 8% during regular trading to $20.55.
The stock is up 26.62% over the past five sessions, up 51.10% over the past six months and up 114.06% year to date. It sits 170.04% above its 52-week low of US$7.610. The intraday swing reached 10.47%.
The Nasdaq Composite is up 0.74% over the past five sessions and up 9.07% year to date.
The life sciences tools and services industry index rose 3.7% over the same period.
The company reported fiscal third-quarter revenue of $50.2 million, up 14% from a year earlier and topping the analyst consensus of $48.8 million. Adjusted EBITDA came in at $1.1 million, turning positive and exceeding the estimate of $551,000. Cryoport raised its full-year 2026 revenue guidance to $197 million to $199 million.
Net loss for the quarter widened 56% year-over-year to $10.9 million. Revenue from commercial cell and gene therapy grew 20%, while life sciences services revenue rose 18% to $28.56 million. During the quarter, the company supported 788 global clinical trials and 23 approved cell and gene therapies.
Based on public media reports. AI-generated; not investment advice.
